Clinical Trials Logo

Ligneous Conjunctivitis clinical trials

View clinical trials related to Ligneous Conjunctivitis.

Filter by:
  • None
  • Page 1

NCT ID: NCT04586062 Available - Clinical trials for Ligneous Conjunctivitis

Sponsor Initiated Expanded Access Protocol, Intermediate-Size Patient Population

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this protocol is to provide compassionate use of Kedrion Human Plasminogen Ophthalmologic Drops to an expanded population of patients diagnosed with ligneous conjunctivitis associated with type I Plasminogen deficiency until product licensure, and/or until a new clinical trial is available and the patients in treatment under Expanded Access are eligible to participate in the new trial.

NCT ID: NCT01554956 Completed - Clinical trials for Ligneous Conjunctivitis

Efficacy/Safety of Human Plasminogen Eye Drop in Ligneous Conjunctivitis Patients

Start date: May 22, 2013
Phase: Phase 2/Phase 3
Study type: Interventional

Kedrion Human Plasminogen, a sterile human plasma-derived plasminogen preparation for topical ocular use will be evaluated for the indication of treatment of ligneous conjunctivitis. KB046 will be an open-label, historically controlled clinical trial. At least 10 subjects with ligneous conjunctivitis, for approximately 20 eyes, will be treated and assessed. All subjects will receive the investigational medicinal product (IMP) for 12 to 48 weeks, with a possibility for extended treatment (Continuation segment)